MARKERS OF THE LUNG CANCER COMPLICATIONS.

Lung cancer (LC) occupies the first place in the structure of cancer morbidity and its prevalence is growing every year. Prognosis of LC course and its complications is a topical task of modern oncology. Further improvement of laboratory prognostic criteria for LC diagnosis and reliable markers of complications of the disease are necessary. Objective - to assess the significance of separate tumor markers in the context of diagnosis and prediction of LC complications. 1071 patients were examined (83% of men and 17% of women aged 24 to 86, average age - 59 years old). Central form of LC was found in 79% of the examined patients, peripheral - in 21% , small-cell histological variant of the disease was detected in 18% of cases and non-small-cell - in 82% (among which adenocarcinoma was detected in 47% of cases, squamous cell carcinoma - in 41%, large-cell carcinoma - in 12%). The ratio of IA, IB, IIA, IIB, III, III and IV stages of the disease was 1: 2: 4: 11: 117: 79: 120. In patients with LC there are increased values of such tumor markers as transforming growth factor ß1, vascular endothelial growth factor, C-reactive protein, osteopontin, osteocalcin, a2-macroglobulin, fibronectin, bulk viscosity of serum, its surface elasticity, tension and relaxation, which is determined by the form of the disease (central, peripheral), its histological variant (small-cell, adenocarcinoma, squamous cell and large-cell carcinoma), the degree of differentiation and the integrated severity of the tumor process, features of metastasis. With the studied immuno-biochemical and physico-chemical tumor adsorption-rheological markers, which correlate with each other, the nature of primary tumor complications (exudative pleurisy, compression syndrome, obstructive atelectasis) is closely related. Values of osteopontin and bulk viscosity have prognostic significance as to relatively unfavorable course of LC, and a high level of surface viscosity is a risk factor for possible complications of the disease.

[TREATMENT OF PATIENTS WITH CHRONIC RECURRENT HERPES VIRUS INFECTION OF GENITAL LOCALIZATION: A CLINICAL STUDY OF FORTEPREN PREPARATION].

AIM: Selection of optimal dosage regimen, length of treatment course (frequency of administration), safety, tolerance and clinical effectiveness evaluation of the medical preparation fortepren in patients with chronical recurrent herpes virus infection of genital localization. MATERIALS AND METHODS: The medical product of antiviral and immune modulating effect--fortepren (sodium polyprenyl phosphate) as a 4 mg/ml solution for injections combined with the base course of acyclic nucleoside acyclovir, 400 mg tablets, held studies. 40 male and female patients participated in the study. After a 10-day acyclovir course (400 mg x 3 times a day) for removing the acute phase, 4 groups of 10 individuals were formed: 1--5 ml (20 mg) of fortepren i/m once at day 13 ± 2 after the start of the study after the completion of the treatment of the acute phase of the disease; 2--5 ml (20 mg) fortepren i/m 3 times at an interval of 21 days; 3--2 ml (8 mg) fortepren i/m 3 times at an interval of 21 days; 4 (control)--5 ml of placebo i/m at remission stage 3 times at an interval of 21 days. Increase of the duration of inter-recurrence period, decrease of the severity of the recurrences, state of skin and mucous damage elements, improvements of immunologic parameters were considered during effectiveness evaluation. RESULTS: Significant differences in the frequency of recurrences of genital herpes were shown for 3 months of observation in experimental and control groups. A significant reduction of genital herpes recurrence frequency from 3.52 ± 0.09 (before treatment) to 2.89 ± 0.08 (after treatment) was noted in patients of group 3 (p < 0.001). The frequency of recurrences in the control group was 3.84 ± 0.10, that was higher than the parameters in all the experimental groups. A significant reduction of the rash area was noted in group 3, moreover, a redution of frequency of detection of clinical manifestations of genital herpes in the form of vesicle elements after treatment in groups 2 (p = 0.02) and 3 (p = 0.005) was found. Evaluation of local symptoms has established that burning have caused minimal discomfort for patients of groups 3 and 4 and itch and soreness--of groups 1 and 3. The least pronounced exacerbations were noted in patients of group 3. Intramuscular administration of fortepren preparation was established to result in the increase of titers of leukocyte virus-induced interferon for the whole duration of treatment. CONCLUSION: An intramuscular dose of 2 ml (8 mg) at recurrence stage 3 times at an interval of 21 days after the completion of the 10-day base course of treatment of the acute phase of chronical recurrent herpes virus infection of genital localization using acyclovir was accepted as an optimal dosage regimen. Analysis of the obtained results has shown an acceptable safety profile and a good level of tolerance for fortepren preparation.